HLA-Bw4-I-80 isoform differentially influences clinical outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 isoforms in rituximab or dinutuximab-based cancer immunotherapy

Amy K. Erbe, Wei Wang, Patrick K. Reville, Lakeesha Carmichael, Kyung Mann Kim, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Wendy B. London, Arlene Naranjo, Fangxin Hong, Michael D. Hogarty, John M. Maris, Julie R. Park, M. F. Ozkaynak, Jeffrey S. Miller, Andrew L. Gilman, Brad Kahl, Alice L. Yu, Paul M. Sondel

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'HLA-Bw4-I-80 isoform differentially influences clinical outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 isoforms in rituximab or dinutuximab-based cancer immunotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences